Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
McKesson
Dow
Merck
Harvard Business School

Last Updated: May 28, 2022

ONZETRA XSAIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Onzetra Xsail, and what generic alternatives are available?

Onzetra Xsail is a drug marketed by Currax and is included in one NDA. There are seventeen patents protecting this drug.

This drug has two hundred and seventy-one patent family members in twenty-nine countries.

The generic ingredient in ONZETRA XSAIL is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

Summary for ONZETRA XSAIL
Drug patent expirations by year for ONZETRA XSAIL
Drug Prices for ONZETRA XSAIL

See drug prices for ONZETRA XSAIL

Recent Clinical Trials for ONZETRA XSAIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Avanir PharmaceuticalsPhase 3
Currax PharmaceuticalsPhase 3

See all ONZETRA XSAIL clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for ONZETRA XSAIL

US Patents and Regulatory Information for ONZETRA XSAIL

ONZETRA XSAIL is protected by twenty-three US patents.

Patents protecting ONZETRA XSAIL

Nasal delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY

Nasal delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY

Nasal administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY

Nasal devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal delivery method
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY

Nasal administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY

Powder delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal delivery device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE

Nasal administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY

Nasal administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ONZETRA XSAIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 See Plans and Pricing See Plans and Pricing
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Harvard Business School
McKesson
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.